Innovative Pharmaceutical Biotech Limited (HK:0399)
:0399
0399 Stock Chart & Stats
HK$0.09
>-HK$0.01(-3.77%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-3.77%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.73
Previous CloseN/A
Volume1.53M
Average Volume (3M)17.09M
Market Cap
HK$399.07M
Enterprise ValueHK$1.34B
Total Cash (Recent Filing)HK$18.07M
Total Debt (Recent Filing)HK$1.09B
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding3,167,207,000
10 Day Avg. Volume17,323,689
30 Day Avg. Volume17,085,593
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)143.85
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Burn TrajectoryReported improvement in cash burn in 2024–2025 versus earlier years indicates management has begun to reduce negative cash flow. If sustained, this structural improvement lowers short-term external funding needs, lengthens runway, and increases the chance of stabilizing operations over the next several months.
Intermittent Profitable YearsThe company has achieved profitability in select years (2022 and 2024), showing the business model can generate positive results under certain conditions. This demonstrates operational levers and margin potential that management can reapply if revenue stabilizes, aiding medium-term recovery prospects.
Lean Operating FootprintA very small headcount suggests a lean cost structure and lower fixed overhead, which enhances flexibility to cut or reallocate costs without large workforce disruptions. Structurally, this reduces ongoing cash burn risk and enables quicker operational adjustments to preserve runway and focus resources.
Bears Say
Negative Equity And High LeverageNegative equity combined with total debt around the high hundreds of millions creates a structural solvency concern. This severely limits access to conventional financing, raises default or covenant risk, and constrains long-term strategic options, undermining durability absent recapitalization.
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow forces reliance on external financing or asset sales to fund operations. This structural cash-generation shortfall reduces ability to invest in growth or R&D and increases dilution or insolvency risk if revenue does not recover.
Multi-year Revenue Decline And Volatile MarginsA sustained revenue contraction culminating in a ~53% fall in 2025, coupled with thin gross margins (~9–13%), means the revenue base is eroded and earnings are highly sensitive to small sales swings. This structural weakness makes consistent profitability and margin recovery more challenging.
Innovative Pharmaceutical Biotech News
0399 FAQ
What was Innovative Pharmaceutical Biotech Limited’s price range in the past 12 months?
Innovative Pharmaceutical Biotech Limited lowest stock price was HK$0.05 and its highest was HK$0.73 in the past 12 months.
What is Innovative Pharmaceutical Biotech Limited’s market cap?
Innovative Pharmaceutical Biotech Limited’s market cap is HK$399.07M.
When is Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date?
Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date is Jun 25, 2026 which is in 79 days.
How were Innovative Pharmaceutical Biotech Limited’s earnings last quarter?
Innovative Pharmaceutical Biotech Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.06.
Is Innovative Pharmaceutical Biotech Limited overvalued?
According to Wall Street analysts Innovative Pharmaceutical Biotech Limited’s price is currently Overvalued.
Does Innovative Pharmaceutical Biotech Limited pay dividends?
Innovative Pharmaceutical Biotech Limited does not currently pay dividends.
What is Innovative Pharmaceutical Biotech Limited’s EPS estimate?
Innovative Pharmaceutical Biotech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innovative Pharmaceutical Biotech Limited have?
Innovative Pharmaceutical Biotech Limited has 3,167,207,000 shares outstanding.
What happened to Innovative Pharmaceutical Biotech Limited’s price movement after its last earnings report?
Innovative Pharmaceutical Biotech Limited reported an EPS of -HK$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.976%.
Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech Limited?
Currently, no hedge funds are holding shares in HK:0399
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovative Pharmaceutical Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.92%
12-Months-Change
Fundamentals
Return on Equity
76.98%
Trailing 12-Months
Asset Growth
-19.45%
Trailing 12-Months
Company Description
Innovative Pharmaceutical Biotech Limited
Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trading of beauty equipment and products in the People's Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, and Research and Development. It is also involved in the securities investment; research, development, and commercialization of oral insulin products; distribution of bio-industrial products; and provision of genetic testing services. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.
Technical Analysis
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
Dingdang Health Technology Group Ltd.
―
Giant Biogene Holding Co. Ltd.
―
Nanjing Sinolife United Co., Ltd. Class H
―